Structure and activity of plasmin and other direct thrombolytic agents

Thrombosis Research

Volumn 122, Issue SUPPL. 3, 2008, Pages

  Novokhatny, Valery ^a  

^a RTP ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFIMEPRASE; FIBRINOLYTIC AGENT; MICROPLASMIN; MINIPLASMIN; PLASMIN; PLASMINOGEN; PRION PROTEIN; RECOMBINANT PLASMIN; STREPTOKINASE; TAL 05 00018; TAL 6003; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG POTENCY; DRUG PURITY; DRUG STORAGE; DRUG STRUCTURE; DRUG SYNTHESIS; ENVIRONMENTAL TEMPERATURE; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SHELF LIFE; THROMBOSIS;

FIBRINOLYTIC AGENTS; HUMANS; PLASMIN; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSIS;

EID: 50849130572     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.06.018     Document Type: Article

References (37)

1. Carmeliet P., and Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost 74 1 (Jul 1995) 429-436
2. Lerch P.G., Rickli E.E., Lergier W., and Gillessen D. Localization of individual lysine-binding regions in human plasminogen and investigation on their complex-forming properties. Eur J Biochem 107 (1980) 7-13
3. Lucas M.A., Fretto L.J., and McKee P.A. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 258 (1983) 4249-4256
4. Wiman B., and Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 84 (1978) 573-582
5. Moroi M., and Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem 251 (1978) 5956-5965
6. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 69 (1976) 209-216
7. Shulman S., Alkjaersig N., and Sherry S. Physicochemical studies on human plasminogen (profibrinolysin) and plasmin (fibrinolysin). J Biol Chem 233 1 (Jul 1958) 91-97
8. Back N., Ambrus J.L., Goldstein S., and Harrisson J.W. In vivo fibrinolytic activity and pharmacology of various plasmin (fibrinolysin) preparations. Circ Res 4 4 (Jul 1956) 440-443
9. Amris C.j., Larsen V., Mogensen B., and Storm O. Clinical studies on an activator free porcine plasmin (plasmin-novo). Sangre (Barc) 61 (1964) 12-18
10. Herndon R.M., Meyer J.S., Jophnson J.F., and Landers J. Treatment of cerebrovascular thrombosis with fibrinolysin. Am J Cardiol 6 (1960) 540-545
11. Ronwin E. Enzymatic properties of bovine plasmin preparations; evidence for similarity to but non-identity with trypsin. Can J Biochem Physiol 34 6 (Nov 1956) 1169-1183
12. Verstraete M. The fibrinolytic system: from Petri dishes to genetic engineering. Thromb Haemost 74 1 (Jul 1995) 25-35
13. Moser K.M. Effects of intravenous administration of fibrinolysin (plasmin) in man. Circulation 20 (1959) 42-55
14. Ambrus J.L., Ambrus C.M., Sokal J.E., et al. Clinical pharmacology of various types of fibrinolytic enzyme preparation. Am J Cardiol 6 (1960) 462-475
15. Cliffton E.E. Review of clinical experience with clotlysing agents. Am J Cardiol 6 (1960) 476-486
16. Davis N.D., Carroll B.J., and Schwartz S.H. Treatment of thrombophlebitis with a fibrinolytic agent. Am J Cardiol 6 (1960) 513-518
17. Egen N.B., Russell F.E., Sammons D.W., et al. Isolation by preparative isoelectric focusing of a direct acting fibrinolytic enzyme from the venom of Agkistrodon contortrix contortrix (southern copperhead). Toxicon 25 11 (1987) 1189-1198
18. Deitcher S.R., Funk W.D., Buchanan J., et al. Alfimeprase: a novel recombinant direct-acting fibrinolytic. Expert Opin Biol Ther 6 12 (Dec 2006) 1361-1369
19. Ouriel K., Cynamon J., Weaver F.A., et al. A phase I trial of alfimeprase for peripheral arterial thrombolysis. J Vasc Interv Radiol 16 8 (Aug 2005) 1075-1083
20. Moll S., Kenyon P., Bertoli L., et al. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. J Clin Oncol 24 19 (Jul 1 2006) 3056-3060
21. Shah A.R., and Scher L. Drug evaluation: alfimeprase, a plasminogen-independent thrombolytic. Drugs 10 (2007) 329-335
22. Nuvelo Inc Press Release: Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development. March 17 2008. http://phx.corporate-ir.net/phoenix.zhtml?c = 109749&p=irol-newsArticle&ID=1119462&highlight=.
23. Nagai N., Demarsin E., Van Hoef B., et al. Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haemost 1 (2003) 307-313
24. Komorowicz E., Kolev K., and Machovich R. Fibrinolysis with des-kringle derivatives of plasmin and its modulation by plasma protease inhibitors. Biochemistry 37 (1998) 9112-9118
25. ThromboGenics NV announces update on its microplasmin development strategy for peripheral vascular disease. ThromboGenics NV. http://www.thrombogenics.com/documents/06_TG_10PAOD_DVTENGFINAL.pdf. August 28, 2007.
26. Gandorfer A., Rohleder M., Sethi C., et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci 45 2 (Feb 2004) 641-647
27. Hunt J., and Novokhatny V. Production and characterization of a novel, recombinantly-modified plasmin molecule. J Thromb Haemost 3 Suppl 1 (2005) P0781
28. Hunt J, Petteway S, Scuderi P, et al. Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with full-length plasmin. Thromb Haemost [In Press].
29. Potter van Loon B.J., Rijken D.C., Brommer E.J., and van der Maas A.P. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 67 (1992) 101-105
30. Robbie L.A., Bennett B., Croll A.M., et al. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost 75 (1996) 127-133
31. Novokhatny V., Taylor K., and Zimmerman T.P. Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis. J Thromb Haemost 1 5 (May 2003) 1034-1041
32. Novokhatny V.V., Jesmok G.J., Landskroner K.A., et al. Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?. Trends Pharmacol Sci 25 2 (Feb 2004) 72-75
33. Stewart D., Kong M., Novokhatny V., Jesmok G., and Marder V.J. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood 101 8 (2003) 3002-3007
34. Markland F.S. Fibrolase, an active thrombolytic enzyme in arterial and venous thrombosis model systems. Adv Exp Med Biol 391 (1996) 427-438
35. Toombs C.F. Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis. Haemostasis 31 (2001) 141-147
36. VJ, Landskroner K., Novokhatny V., Zimmerman T.P., Kong M., Kanouse J.J., and Jesmok G. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 86 3 (2001) 739-745
37. Shlansky-Goldberg RD, Matsumoto AH, Baumbach GA, Siegel JB, Raabe RD, Murphy TP, Deng C, Dawkins JR, Marder VJ. A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion. J Thromb Haemost 2008 Apr 2;in press.